Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf544 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Nai-Chia Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Breakthrough T1D.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Continuous glucose monitoring (CGM) metrics are increasingly used to study the relationship between glycemic control and diabetic complications; however, the correlated glucose measurements and unequal follow-up times in real-world CGM data necessitate more advanced analytical approaches to yield unbiased estimates.
Objective
This retrospective case-cohort study aimed to estimate longitudinal changes in time in range (TIR) on progression to diabetic retinopathy (DR) among patients with type 1 diabetes (T1D).
Methods
This was a retrospective case-cohort study among patients with T1D, using CGM devices. We analyzed linked CGM and electronic health record data from 161 patients with T1D, with long-term follow-up for incident DR diagnoses. TIR was defined as time spent in sensor glucose between 70 and 180 mg/dL. Multilevel mixed-effects parametric survival models and Markov models were constructed to obtain effects of TIR (eg, hazard ratios [HRs]) and lifetime trajectories of developing retinopathy and blindness, respectively.
Results
A retrospective case cohort of 161 patients with T1D (mean duration 13.7 years) included 71 cases (baseline glycated hemoglobin A1c [HbA1c] of 8.2%) and 90 controls (baseline HbA1c of 7.3%). A 10% increase in TIR was associated with a modestly lower risk of retinopathy progression (HR 0.88; 95% CI, 0.78-0.98) and an estimated prevention of 39 cases of blindness per 1000 individuals over time (TIR 70% vs 40%). Economic simulation modeling suggested $2581 lower costs per person and a gain of 0.13 quality-adjusted life years (QALYs).
Conclusion
These findings can guide real-world CGM studies and support diabetes simulation models to predict future treatment outcomes from CGM metrics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
ORCID-Profile: Nai-Chia Chen, Viral N Shah, Robert Brett McQueen
Förderung
- Breakthrough T1D
Zitieren
APA
Chen, N. C., Shah, V. N., & McQueen, R. B. (2026). Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf544
Vancouver
Chen NC, Shah VN, McQueen RB. Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf544
BibTeX
@article{Chen2026,
author = {Chen, Nai-Chia and Shah, Viral N and McQueen, Robert Brett},
title = {Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf544}
}
EUVIMED